Ryan Livingston

Research presented at the American Heart Association Scientific Sessions 2025 has emphasized the progress which still needs to be made in treating CHD.

Eli Lilly and Company’s investigative therapy provided effective and safe weight loss treatment with limited adverse events.

Catch up on the groundbreaking FDA approvals, key trial updates, and more news from the last month.

Stay up to date with the groundbreaking FDA decisions, critical trial updates, and more news from the last month.

Based on results from the THRIVE and THRIVE-2 phase 3 studies, this Biologics License Application includes a request for Priority Review.

Catch up with groundbreaking FDA decisions, exciting new GLP-1 news, and more.

Alterations in appetite and weight may have influenced abdominal adiposity, as well as inflammatory and cardiometabolic markers.

Following a Type A meeting with the FDA, the ophthalmic formulation of bevacizumab is back on track towards a potential US approval.

Exposure to nonoptimal temperatures have shown an association with deaths among patients with heart failure.

Recent research has highlighted the influence of minor beat-to-beat changes in blood pressure on the left side of the brain.

A recent European study has confirmed prior American data showing the predictive ability of this combination measurement in healthy patients.

A secondary analysis of the J-DOIT3 study highlights previously undertreated factors in the progression of diabetic retinopathy in patients with type 2 diabetes.

Preeclampsia, gestational diabetes, preterm delivery, large for gestational age, and other hypertensive disorders of pregnancy are now risk factors.

Immediate iFR-guided PCI and deferred cardiac stress MRI-guided PCI showed no significant difference, allowing patients to complete treatment in 1 session.

In a post-hoc analysis of the KINGFISHER trial, brolucizumab resulted in improved BCVA and anatomical outcomes regardless of prior anti-VEGF treatment.

The investigative GLP-1/GCG dual receptor agonist led to a higher proportion of participants achieving HbA1c and body weight improvements from baseline.

A post hoc analysis of the PLIS study has highlighted the comparative effectiveness of glucose levels in achieving prediabetes remission.

FDA approves Omvoh (mirikizumab-mrkz) for monthly maintenance of ulcerative colitis, simplifying treatment for patients with this chronic condition.

Patients experienced significantly fewer thromboembolic complications when treated with ICE, indicating its comparatively noninferior safety and efficacy.

The phase 3 ZENITH trial showed sotatercept’s superiority over placebo in reducing morbidity and mortality outcomes in adults with WHO FC III or IV PAH.

Although no direct correlation can be drawn, these findings suggest a possible ocular benefit from GLP-1 RAs compared to other weight loss drugs.

Risks of myocardial infarction, stroke, heart failure, and other debilitating cardiovascular diseases may be directly influenced by adolescent sugar intake.

GLP-1 RAs may offer benefits beyond adiposity reduction in patients with atherosclerotic cardiovascular disease.

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

A recent study from Duke University spotlighted papSCAR’s substantial association with both cardiovascular mortality and arrhythmia.

A total of 8 acute and chronic disease factors, including hypertension, obesity, and physical inactivity, compound to increase mortality and CVD risk.

This approval represents an alternative method for approaching this undertreated disease, shortening recovery while minimizing invasiveness.

Rybelsus marks the first oral GLP-1 for major adverse cardiovascular events in adult patients with T2D, opening a new cardiovascular treatment pathway.

Results from the phase 3 trial show consistent reductions in annualized bleeding rate after 12 months of once-weekly treatment.

A pooled cohort analysis of the phase 3 BROOKLYN and BROADWAY trials spotlighted obicetrapib’s impact on patients at risk of cardiovascular mortality.